We push the limits of what's possible for our patients.
Better Cells for Better Therapies®
Cirapot Oncology is a clinical-stage biopharmaceutical company dedicated to advancing a first-in-class pipeline of innovative off-the-shelf cellular immunotherapies for patients with serious diseases.
To develop better cell therapies, we utilize a proprietary cell programming approach that enables us to engineer human induced pluripotent stem cells (iPSCs) with advanced synthetic controls of cellular function. We establish clonal master iPSC lines that provide a renewable foundation for the consistent manufacture of our therapeutic candidates.
Meet Our Team
Dermatologist
Anesthesiologist
Dermatologist
Radiology Specialist
About Our Clinic
Similar to master cell lines used in the production of biologic medicines, our proprietary platform is designed to support scalable manufacturing of multiplex-engineered cellular immunotherapies with off-the-shelf availability. This approach offers the flexibility to be used independently or alongside existing standards of care, expanding access to patients around the world.
Through our iPSC platform, Ciropat Onocology continues to advance multiplex-engineered T-cell and natural killer (NK) cell therapies that integrate innovative synthetic controls and multiple therapeutic mechanisms, supporting the next generation of precision medicine.
ACCEPTED
INSURANCE:
